You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015
|
|---|---|
| Published in |
Antimicrobial Agents and Chemotherapy, August 2017
|
| DOI | 10.1128/aac.00472-17 |
| Pubmed ID | |
| Authors |
James A. Karlowsky, Krystyna M. Kazmierczak, Boudewijn L. M. de Jonge, Meredith A. Hackel, Daniel F. Sahm, Patricia A. Bradford |
| Abstract |
The combination of the monobactam, aztreonam, and the non-β-lactam β-lactamase inhibitor, avibactam, is currently in clinical development for the treatment of serious infections caused by metallo-β-lactamase (MBL)-producing Enterobacteriaceae, a difficult to treat subtype of carbapenem-resistant Enterobacteriaceae for which therapeutic options are currently very limited. The present study tested clinically significant isolates of Enterobacteriaceae (n=51,352) and Pseudomonas aeruginosa (n=11,842) collected from hospitalized patients in 208 medical center laboratories from 40 countries from 2012 to 2015 for in vitro susceptibility to aztreonam-avibactam, aztreonam, and comparator antimicrobial agents using standard broth microdilution methodology. Avibactam was tested at a fixed concentration of 4 μg/ml in combination with two-fold dilutions of aztreonam. The concentration of aztreonam-avibactam and aztreonam inhibiting 90% of isolates (MIC90) was 0.12 and 64 μg/ml for all Enterobacteriaceae isolates; >99.9% of all isolates and 99.8% of meropenem-nonsusceptible isolates (n=1,498) were inhibited by aztreonam-avibactam at a concentration of ≤8 μg/ml. PCR and DNA sequencing identified 267 Enterobacteriaceae isolates positive for MBL genes (NDM, VIM, IMP); all Enterobacteriaceae carrying MBLs demonstrated aztreonam-avibactam MICs of ≤8 μg/ml and a MIC90 of 1 μg/ml. Against all P. aeruginosa isolates tested, the MIC90 of both aztreonam-avibactam and aztreonam was 32 μg/ml; against MBL-positive P. aeruginosa (n=452) MIC90 values for aztreonam-avibactam and aztreonam were 32 and 64 μg/ml, respectively. The current study demonstrated that aztreonam-avibactam possessed potent in vitro activity against a recent, sizeable global collection of Enterobacteriaceae clinical isolates, including isolates that were meropenem-non-susceptible, and against MBL-positive isolates of Enterobacteriaceae, for which there are few treatment options. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 40% |
| Belgium | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 67 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 13% |
| Researcher | 9 | 13% |
| Student > Bachelor | 7 | 10% |
| Student > Postgraduate | 7 | 10% |
| Student > Ph. D. Student | 5 | 7% |
| Other | 10 | 15% |
| Unknown | 20 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 16% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Immunology and Microbiology | 6 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Agricultural and Biological Sciences | 4 | 6% |
| Other | 6 | 9% |
| Unknown | 29 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2023.
All research outputs
#3,027,370
of 25,382,440 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#1,892
of 15,580 outputs
Outputs of similar age
#53,351
of 324,941 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#63
of 230 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 15,580 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 230 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.